Drug ID:Drug178
Drug Name:Dersalazine sodium
CID:135565341
DrugBank ID:DB06251
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT00808977
Molecular Formula:C35H31N6NaO4
Molecular Weight:622.6 g/mol
Isomeric SMILES:CC1=NC2=C(N1CC3CCN(CC3)C(=O)/C=C(/C4=CC=CC=C4)\\C5=CC=C(C=C5)N=NC6=CC(=C(C=C6)O)C(=O)[O-])C=CN=C2.[Na+]
Synonyms:Dersalazine sodium; Sodium dersalazine; UR-12746S; UNII-BAB844203H; 367249-56-7; BAB844203H; Benzoic acid, 2-hydroxy-5-(2-(4-((1Z)-3-(4-((2-methyl-1H-imidazo(4,5-c)pyridin-1-yl)methyl)-1-piperidinyl)-3-oxo-1-phenyl-1-propen-1-yl)phenyl)diazenyl)-, sodium salt (1:1); sodium;2-hydroxy-5-[[4-[(Z)-3-[4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]piperidin-1-yl]-3-oxo-1-phenylprop-1-enyl]phenyl]diazenyl]benzoate; Dersalazine (sodium); DERSALAZINE SODIUM [WHO-DD]
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
No data available

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT00808977 A Phase II Study to Explore the Safety and Activity of Dersalazine in Patients With Mild to Moderate Ulcerative Colitis PHASE2 COMPLETED Palau Pharma S.L.U. Ulcerative Colitis DRUG: Dersalazine sodium|DRUG: Mesalazine|DRUG: P… Details
NCT07169123 Protease Regulation and Impact of Sodium as Mechanisms of Inflammation in IBD NULL NOT_YET_RECRUITING McMaster University Crohns Disease None Details
NCT05456763 Butyrate in Pediatric Inflammatory Bowel Disease NA COMPLETED Centre of Postgraduate Medical Education Inflammatory Bowel Diseases DIETARY_SUPPLEMENT: sodium butyrate|OTHER: placebo Details
NCT05249023 Mode of Action of Butyrate in the Human Colon NA COMPLETED Örebro University, Sweden Irritable Bowel Syndrome (IBS)|Healthy OTHER: Sodium butyrate bolus Details
NCT05013060 The Efficacy of Sodium Butyrate and Probiotics in Patients With Irritable Bowel Syndrome NA COMPLETED Nordic Biotic Sp. z o.o. Irritable Bowel Syndrome DIETARY_SUPPLEMENT: Probiotics and microcapsulate… Details
NCT04879914 Analysis of Microbiota Changes Induced by Microencapsulated Sodium Butyrate in Patients With Inflammatory Bowel Disease NA COMPLETED University of Padova Inflammatory Bowel Diseases|Irritable Bowel Syndr… DIETARY_SUPPLEMENT: Butyrate|DIETARY_SUPPLEMENT: … Details
NCT04456517 Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy PHASE2 TERMINATED Vanderbilt University Medical Center Crohn's Disease|Inflammatory Bowel Disease DRUG: Ranolazine|DRUG: Placebo Details
NCT03681067 A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's Disease PHASE1|PHASE2 COMPLETED University of Birmingham Crohn Disease DRUG: GSK1070806|DRUG: Placebo- sodium chloride Details
NCT03593252 Bowel Preparation in Elective Pediatric Colorectal Surgery NA UNKNOWN McMaster University Colostomy|Hirschsprung Disease - Pull Through|Nec… DRUG: Senna|DRUG: Sodium Picosulfate, Magnesium O… Details
NCT03581149 Tolerability and Efficacy of Sodium Picosulfate/Magnesium Citrate Versus PEG/Ascorbic Acid in Ulcerative Colitis Patients PHASE4 UNKNOWN American University of Beirut Medical Center Ulcerative Colitis DRUG: Sodium Picosulfate/Magnesium Citrate Laxati… Details
NCT03110198 Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis PHASE4 UNKNOWN Xijing Hospital of Digestive Diseases Ulcerative Colitis, Unspecified DRUG: Mesalazine|DRUG: hydrocortisone sodium succ… Details
NCT02769494 The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer PHASE3 WITHDRAWN Xijing Hospital of Digestive Diseases Crohn's Disease|Oral Ulcer DRUG: Mesalazine Sustained-Release Tablets|DRUG: … Details
NCT00912301 Cheno Effect on Transit in Health and IBS-C PHASE2 COMPLETED Mayo Clinic Constipation-predominant Irritable Bowel Syndrome DRUG: Sodium chenodeoxycholate (NaCDC)|OTHER: Pla… Details
NCT00867438 Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium, Administered Add-on Therapy PHASE2 COMPLETED Cosmo Technologies Ltd Ulcerative Colitis PROCEDURE: Sigmoidoscopy Details
NCT00829218 Clinical Trial Examining Effects of Monosodium Glutamate (MSG) on Irritable Bowel Syndrome (IBS) and Fibromyalgia (FM) NA COMPLETED Oregon Health and Science University Irritable Bowel Syndrome|Fibromyalgia OTHER: Glutamate additive-free diet|OTHER: Placeb… Details
NCT00618202 A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Balsalazide Disodium 750 mg Capsules Under Fasting Conditions NA COMPLETED Roxane Laboratories Ulcerative Colitis DRUG: Balsalazide Details
NCT00486031 Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study PHASE3 COMPLETED Bausch Health Americas, Inc. Inflammatory Bowel Disease|Ulcerative Colitis DRUG: Balsalazide Disodium Details
NCT00408174 Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis PHASE3 COMPLETED Bausch Health Americas, Inc. Inflammatory Bowel Disease|Ulcerative Colitis DRUG: Balsalazide disodium Details
NCT00269438 New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis PHASE3 COMPLETED Bausch Health Americas, Inc. Ulcerative Colitis DRUG: 5 ASA, enemas, suppositories, corticosteroi… Details
JPRN-UMIN000046015 A prospective, controlled, randomized, assessor-blind, comparative study of a new oral bowel cleanser (Sodium Picosulfate/Magnesium Citrate) versus existing oral bowel cleanser (Magnesium Citrate) in pediatric colonoscopy preparation. - A prospective, con NULL Not Recruiting Saitama children's Medical Center Division of Gastroenterology and Hepatology Inflammatory bowel disease, Functional gastrointe… PICOPREP MAGCOROL Powder Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

Safety and activity of dersalazine sodium in patients with mild-to-moderate act…

PMID: 25192498
Year: 2014
Relationship Type: Treatment Score: 9.3

BACKGROUND: Dersalazine sodium is an inhibitor of platelet activator factor with potential efficacy in patients with ulcerative colitis through an al…

View Details
The intestinal anti-inflammatory effect of dersalazine sodium is related to a d…

PMID: 21790535
Year: 2012
Relationship Type: Association Score: 6.1

Intestinal dysbiosis is thought to confer susceptibility to inflammatory bowel disease (IBD), but it is unknown whether dynamic changes in the micro…

View Details